In human T265-2c malignant peripheral nerve sheath tumor cells, sabutoclax (6 µM, 24 h) reduced CXCL12 mRNA and viable cell number relative to untreated cells. The study identifies its reagent as AdooQ A12823. These concurrent responses do not by themselves establish a direct CXCL12 target or a sabutoclax-specific PARP1 mechanism. [3]
BH3-peptide displacement from antiapoptotic Bcl-2 family proteins
Biochemical assay · Recombinant Bcl-XL, Bcl-2, Mcl-1 and Bfl-1 in fluorescence-polarization displacement assays. [1]
Compound 11 displaced BH3 peptides with submicromolar IC50 values in the reported assay panel. These are displacement endpoints, not cellular treatment concentrations or proof of selective cellular mechanism.
Literature-Reported Treatment Conditions
- Treatment concentration
- Compound concentration-response series; IC50 values are assay results.
- Exposure duration
- Bcl-XL: 10 min preincubation, then 30 min with peptide; Bcl-2/Mcl-1: 2 min preincubation, then 10 min with peptide.
- Method
- Competitive fluorescence polarization in PBS; wild-type/mutant Bak peptide controls described.
- Reported limits
- Bfl-1-specific peptide/incubation conditions are not separately detailed in the retrieved main methods; no SI was retrieved.
Methods and source locations
Compound reported in the paper: Sabutoclax; Compound label in the paper: Compound 11 (BI-97C1)
Reported research material; no equivalence to a current Adooq lot or independent stereochemical lot verification is established.
Table 2; Figure 2A; Experimental Section: Fluorescence Polarization Assays (FPAs)
Bcl-XL BH3-peptide displacement: Competitive fluorescence polarization; mean ± SE, three independent experiments per FPA methods. — Table 2, compound 11 row; Experimental Section: Fluorescence Polarization Assays (FPAs)
Bcl-2 BH3-peptide displacement: Competitive fluorescence polarization; mean ± SE, three independent experiments per FPA methods. — Table 2, compound 11 row; Experimental Section: Fluorescence Polarization Assays (FPAs)
Mcl-1 BH3-peptide displacement: Competitive fluorescence polarization; mean ± SE, three independent experiments per FPA methods. — Table 2, compound 11 row; Experimental Section: Fluorescence Polarization Assays (FPAs)
Bfl-1 BH3-peptide displacement: Competitive fluorescence polarization; mean ± SE, three independent experiments per FPA methods. — Table 2, compound 11 row; Experimental Section: Fluorescence Polarization Assays (FPAs)
CXCL12 expression and viable cell number in T265-2c MPNST cells
Cell-based study · Human NF1-derived T265-2c malignant peripheral nerve sheath tumor cells. [3]
Sabutoclax at 6 µM for 24 h reduced CXCL12 mRNA and viable cell number relative to untreated cells. Separate single-agent comparator treatments were AT101, ABT-737, obatoclax and, for the expression assay, desferrioxamine.
Literature-Reported Treatment Conditions
- Treatment concentration
- 6 µM
- Exposure duration
- 24 h
- Method
- qRT-PCR for CXCL12, normalized to 18S by ΔΔCT; calcein-AM viable-cell assay; treatment medium contained 2% FBS.
- Co-treatment
- None; comparator drugs were separate treatment groups.
- Reported limits
- Solvent vehicle and catalog lot/purity not specified in the read main text. Untreated rather than a separately described solvent control was used.
Methods and source locations
Compound reported in the paper: Sabutoclax; Compound label in the paper: SBX
Reported research material; no equivalence to a current Adooq lot or independent stereochemical lot verification is established.
Results s2_2; Figures 2 and 4A; Methods s4_1–s4_3, s4_5 and s4_7
CXCL12 mRNA relative to untreated T265-2c cells: qRT-PCR; mean ± SD; ANOVA followed by Dunnett’s post-hoc test. — Figure 2 (SBX 6 µM); Results s2_2; Methods s4_5 and s4_7
Viable T265-2c cell number relative to untreated cells: Calcein-AM conversion; mean ± SD; ANOVA followed by Dunnett’s post-hoc test. — Figure 4A (SBX 6 µM); Methods s4_3 and s4_7
Functional testing of mitochondrial activity and intact-cell toxicity
Cell-based study · Murine leukemia model lines dependent on human BCL-2, BCL-XL, MCL-1 or BFL-1, plus a BAX/BAK double-knockout control line. [2]
In paired concentration-response assays, sabutoclax preferentially killed MCL-1- and BFL-1-dependent intact cells, but its limited mitochondrial activity at higher concentrations was also seen in BAX/BAK-deficient cells. It did not meet this study’s functional criteria for a potent direct BH3 mimetic.
Literature-Reported Treatment Conditions
- Treatment concentration
- Concentration-response series; Discussion identifies mitochondrial activity at concentrations >1 µM.
- Exposure duration
- 1 h for direct mitochondrial iBH3 assay; 24 h for intact-cell Annexin V assay.
- Method
- Cytochrome c loss by flow cytometry after exposure in digitonin-permeabilized cells; parallel Annexin V/Hoechst testing in intact cells.
- Vehicle
- DMSO stock solvent; drug-free buffer controls and fluorescence-minus-one controls for iBH3 normalization.
- Co-treatment
- None.
- Reported limits
- No catalog lot, analytical form confirmation, or sabutoclax-specific fitted potency reported in the read text; exact graph values not reconstructed.
Methods and source locations
Compound reported in the paper: Sabutoclax; Compound label in the paper: Sabutoclax
Reported research material; no equivalence to a current Adooq lot or independent stereochemical lot verification is established.
Figures 1 and 2, row labeled Sabutoclax; Methods Sec3–Sec7; Results Sec8 and Discussion Sec9
Direct mitochondrial cytochrome c release across dependency panel including BAX/BAK DKO: iBH3, 1 h; N ≥ 6; error bars SD. — Figure 2 row explicitly labeled Sabutoclax (graphic C; caption d); Figure 1; Discussion Sec9
Intact-cell killing in the antiapoptotic dependency panel: Annexin V/Hoechst after 24 h; N ≥ 3; error bars SD. — Figure 2 row labeled Sabutoclax, right plot; Results Sec8; Methods Sec6